No Data
No Data
Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Ultragenyx Pharmaceutical (RARE)
Where Insulet Stands With Analysts
In the last three months, 6 analysts have published ratings on Insulet (NASDAQ:PODD), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their recent ratings,
Insulet Initiated at Buy by Redburn Atlantic
Insulet Initiated at Buy by Redburn Atlantic
Express News | Redburn Atlantic Initiates Coverage On Insulet With Buy Rating, Announces Price Target of $235
Insulet(PODD.US) Director Sells US$596.97K in Common Stock
$Insulet(PODD.US)$ Director Scannell Timothy J sold 3,300 shares of common stock on May 28, 2024 at an average price of $180.9 for a total value of $596.97K.Source: Announcement What is statement of c
Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing
Timothy J Scannell, Director, on May 28, 2024, sold 3,300 shares in Insulet (PODD) for $596,970. Following the Form 4 filing with the SEC, Scannell has control over a total of 42,586 shares of the com
No Data